Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...

CStone, the drug’s developer, previously announced similar deals with various pharmaceutical companies to expand sugemalimab ...

Health In Tech announced new partnerships that it says will allow it to introduce a new self-funded health plan. 1 The ...

Approval was based on results from multiple studies, which demonstrated a slowing of cognitive decline in patients with ...

The government agency says X no longer suits its communication needs.

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in ...

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.

Campaign encourages the use of low-dose aspirin to help reduce the risk of preeclampsia and the complications that come with ...

Veeva’s vice president of commercial strategy discusses how streamlining their processes with a single goal in mind can ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).